febuxostat has been researched along with Cardiac Remodeling, Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF | 1 |
| Ito, O; Kohzuki, M; Kurosawa, R; Miura, T; Nakamura, T; Namai-Takahashi, A; Sakuyama, A; Takahashi, J | 1 |
2 other study(ies) available for febuxostat and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Topics: Animals; Collagen; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Male; NADPH Oxidases; Phosphorylation; Rats, Inbred Dahl; Reactive Oxygen Species; Renin-Angiotensin System; Sodium Chloride, Dietary; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2019 |